Last reviewed · How we verify
BIOLOGICAL ASSESSMENT — Competitive Intelligence Brief
phase 3
Oncology
Biologic
Live · refreshed every 30 min
Target snapshot
BIOLOGICAL ASSESSMENT (BIOLOGICAL ASSESSMENT) — Centre Hospitalier Universitaire Dijon. BIOLOGICAL ASSESSMENT is a drug that evaluates the biological effects of a substance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BIOLOGICAL ASSESSMENT TARGET | BIOLOGICAL ASSESSMENT | Centre Hospitalier Universitaire Dijon | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BIOLOGICAL ASSESSMENT CI watch — RSS
- BIOLOGICAL ASSESSMENT CI watch — Atom
- BIOLOGICAL ASSESSMENT CI watch — JSON
- BIOLOGICAL ASSESSMENT alone — RSS
Cite this brief
Drug Landscape (2026). BIOLOGICAL ASSESSMENT — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-assessment. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing